Introduction – Are we looking at the sunset season of Iron Ore Investments or are we looking at the beginning of a long Spring and Summer Season Investors in the iron ore sector have been dwelling on global market chatter of a declining iron ore price as the giant Simandou Iron Ore mine ships its first shipment of high0grade ore. The street talk is that the imminent 120 million tonnes per annum production coming out of Guinea is going to drive iron ore pricing to the sub US

Control Bionics Limited (ASX: CBL) has announced a new agreement with Tobii Dynavox, a global leader in Augmentative and Alternative Communication (AAC), to evaluate a potential U.S. distribution partnership for its NeuroNode® technology. The agreement initiates a six-month pilot program across five north-western U.S. states, positioning NeuroNode alongside Tobii Dynavox’s established communication aids.

When it comes to spotting undervalued potential in biotech, I often look for companies that are not only developing novel technologies but also demonstrating clear paths to commercialisation. This month, three small-cap names on the ASX have really caught my attention: Memphasys Limited (ASX: MEM), Control Bionics (ASX: CBL), and dorsaVi Ltd (ASX: DVL). Each is on a very different mission, but all three are making measurable progress—and investors are starting to notice.